https://www.thebodypro.com/category/atazanavir-reyataz

Atazanavir (Reyataz)

The Latest

Fist raised at Black Lives Matter Protest
News

This Week in HIV Research: The Racism of Perceived Risk

June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir Img
Kidney

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir

Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.

IDWeek

What's Hot in HIV Clinical Science

What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study Img
IAS (International AIDS Society) Conference

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study

Atazanvir/ritonavir at 200/100 mg was found to be non-inferior to atazanvir/ritonavir at 300/100 mg, according to study results presented at IAS 2015.

HIV Antiretroviral Study Highlights From IAS 2015 Img
IAS (International AIDS Society) Conference

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

Conference Coverage

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

Transplacental Transfer of Atazanavir and Neonatal Hyperbilirubinemia

Results from a study evaluating the transplacental transfer of atazanavir (ATV) and the incidence of hyperbilirubinaemia in ATV exposed neonates were presented at the 14th International Workshop on Clinical Pharmacology. In this analysis, foetal cor...

Recent Changes to the Reyataz (Atazanavir Sulfate) Capsule Labeling

Recently FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes. Section 5 Warnings and Precautions was revised to include cholelithiasis as follows: Nephrolithiasis and Cholelithiasis Cases of n...

Conference Coverage

Reyataz and Kidney Stones

Reyataz, one of two preferred HIV protease inhibitor (PI) medications under U.S. treatment guidelines, is associated with the risk of kidney stones and other potential renal abnormalities. According to Japanese researchers, people taking Norvir-boost...

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors Img
News

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritona...